Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare stock trading at $676.64 (as of 2026-07-17), with a market capitalization of $72.87B and a trailing P/E of 16.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines, including EYLEA injection and Dupixent injection, and it also earns collaboration revenue from partners such as Sanofi.
Reported results are structurally linked to Dupixent, with a meaningful portion of revenue also coming from collaboration arrangements (for example, Sanofi collaboration revenue), so changes in how Dupixent-related economics are recorded can drive the profit outcome.
Business quality (Mixed): Key product and collaboration lines are clear, but the provided data does not include an official reportable segment breakdown that cleanly sums to total revenue.
Valuation: At 15× earnings, REGN trades 8% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $676.64 |
| Market Cap | $72.87B |
| P/E Ratio | 16.6 |
| EV / EBITDA | 16.9 |
| Price / Book | 2.32 |
| Price / Sales | 5.18 |
| FCF Yield | 9.0% |
| DCF Value (model) | $664.45 |
| DCF Upside vs Price | -1.8% |
| Revenue (TTM) | $14.34B |
| Net Margin | 31.4% |
| Revenue Growth (YoY) | 1.0% |
| EPS Growth (YoY) | 5.3% |
| FCF Growth (YoY) | 11.3% |
| Altman Z-Score | 7.02 (safe) |
| Stock P/E | 16.6 |
| Sector P/E (Healthcare) | 21.4 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -22.5% |
| vs Industry | -2.1% |
| Top Institutional Holder | VANGUARD GROUP INC ($7.00B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Leonard S. Schleifer |
| Employees | 15,158 |
| Country | US |
| IPO Date | 1991-04-02 |
Data as of 2026-07-17.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.